SlideShare a Scribd company logo
1 of 1
Download to read offline
THE INTELLECTUAL PROPERTY MINUTE
                                 JANUARY 2010: RESTRICTION PRACTICE

We have seen the increasing use of restriction and election of species requirement by patent examiners over the
last several years. Here are some suggestions for preventing and overcoming restriction requirements.

                                                  Pre-Restriction
When drafting the patent application, prepare method and product claims so they contain as many similar
limitations as possible. This technique will reduce the ability for the examiner to say that the method as claimed
can be used to make a different product or that the product as claimed can be made by a different method. Also,
to anticipate an election of species requirement, draft one claim as broad as possible so that it can be considered
a generic claim and also include a linking claim.

                                               Replying to Restrictions
        On receipt of a restriction requirement, take a hard look at the requirement itself and the underlying
reasoning. Some of the mistakes made by Examiners include: (1) applying PCT rules to U.S. applications, (2)
not accounting for all generic or linking claims, (3) forcing a species election where they are not mutually
exclusive, (4) imposing a restriction rather than an election of species, and (5) not providing sufficient reasoning
to support the argument that the method as claimed can be used to make a different product or that the product
as claimed can be made by a different method. Look for generic claims and linking claims that can be used to
limit the impact of the restriction requirement. And remember, there is nothing precluding you from amending
the claims to defeat the restriction requirement, i.e., adding a generic claim or a linking claim, as well as
amending the generic claim to include all of the species. 90% of the time, one of these problems exist and can
be used as a basis for traversing the restricting requirement.


                                                 Post-Restriction
Win or lose, there are certain actions that can be taken lessen the impact of restriction practice. For an election
of specie requirement, make sure that the generic claim is an independent claim that contains both the elected
specie and the non-elected specie(s). When the elected specie has been allowed, the Examiner must examine
the non-elected species. But if the claim is already an independent claim, and the Examiner has already
determined it is allowable, the Examiner will likely do nothing more. But if the elected specie is in a dependent
claim, the Examiner will continue the examination process.

Also keep in mind your ability to take advantage of rejoinder practice. With rejoinders, the Applicant can rejoin
claims after the product and method claims have been restricted. Where the Applicant elected and obtained
allowance of a product claim, the process claims may be rejoined provided that the process claims depend from
or include all the limitations of the allowable product claim. The best method for keeping rejoinder a viable
option is to not cancel the method claims; rather, continue to amend the method claims throughout prosecution.

More Related Content

What's hot

Vemurafenib - Comprehensive patent search
Vemurafenib   - Comprehensive patent searchVemurafenib   - Comprehensive patent search
Vemurafenib - Comprehensive patent searchReportsnReports
 
The 510(k) Process
The 510(k) ProcessThe 510(k) Process
The 510(k) ProcessMichael Swit
 
10 Facts to pass the RAC (Regulatory Affairs Certification)
10 Facts to pass the RAC (Regulatory Affairs Certification)10 Facts to pass the RAC (Regulatory Affairs Certification)
10 Facts to pass the RAC (Regulatory Affairs Certification)pauljhon43
 
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...NAMSA
 
Nevirapine - Comprehensive patent search
Nevirapine  - Comprehensive patent searchNevirapine  - Comprehensive patent search
Nevirapine - Comprehensive patent searchReportsnReports
 
Regulatory Affairs Certification Dumps
Regulatory Affairs Certification DumpsRegulatory Affairs Certification Dumps
Regulatory Affairs Certification DumpsExamure4
 
Treprostinil - Comprehensive patent search
Treprostinil  - Comprehensive patent searchTreprostinil  - Comprehensive patent search
Treprostinil - Comprehensive patent searchReportsnReports
 
Liraglutide - Comprehensive patent search
Liraglutide  - Comprehensive patent searchLiraglutide  - Comprehensive patent search
Liraglutide - Comprehensive patent searchReportsnReports
 
Regulatory and Quality Affairs: Answers to FDA and ISO Gray Areas
Regulatory and Quality Affairs: Answers to FDA and ISO Gray AreasRegulatory and Quality Affairs: Answers to FDA and ISO Gray Areas
Regulatory and Quality Affairs: Answers to FDA and ISO Gray AreasApril Bright
 
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...April Bright
 
Rifaximin - Comprehensive patent search
Rifaximin  - Comprehensive patent searchRifaximin  - Comprehensive patent search
Rifaximin - Comprehensive patent searchReportsnReports
 
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017Avoid Post-M&A Supply Chain Surprises - OMTEC 2017
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017April Bright
 
The CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsThe CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsMedpace
 
Dr. Piotr Iwanowski - 6th Clinical Research Conference
Dr. Piotr Iwanowski - 6th Clinical Research ConferenceDr. Piotr Iwanowski - 6th Clinical Research Conference
Dr. Piotr Iwanowski - 6th Clinical Research ConferenceStarttech Ventures
 
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-FinalWill Zasadny
 
RAC US Study Guide
RAC US Study GuideRAC US Study Guide
RAC US Study Guideolivia_43
 
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...April Bright
 
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Will Roettger
 
Chelsea Therapeutics - Northera NOH 2011 Market Research Plan
Chelsea Therapeutics -  Northera NOH 2011 Market Research PlanChelsea Therapeutics -  Northera NOH 2011 Market Research Plan
Chelsea Therapeutics - Northera NOH 2011 Market Research PlanWill Roettger
 

What's hot (20)

Vemurafenib - Comprehensive patent search
Vemurafenib   - Comprehensive patent searchVemurafenib   - Comprehensive patent search
Vemurafenib - Comprehensive patent search
 
The 510(k) Process
The 510(k) ProcessThe 510(k) Process
The 510(k) Process
 
10 Facts to pass the RAC (Regulatory Affairs Certification)
10 Facts to pass the RAC (Regulatory Affairs Certification)10 Facts to pass the RAC (Regulatory Affairs Certification)
10 Facts to pass the RAC (Regulatory Affairs Certification)
 
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
 
Nevirapine - Comprehensive patent search
Nevirapine  - Comprehensive patent searchNevirapine  - Comprehensive patent search
Nevirapine - Comprehensive patent search
 
Regulatory Affairs Certification Dumps
Regulatory Affairs Certification DumpsRegulatory Affairs Certification Dumps
Regulatory Affairs Certification Dumps
 
Treprostinil - Comprehensive patent search
Treprostinil  - Comprehensive patent searchTreprostinil  - Comprehensive patent search
Treprostinil - Comprehensive patent search
 
Liraglutide - Comprehensive patent search
Liraglutide  - Comprehensive patent searchLiraglutide  - Comprehensive patent search
Liraglutide - Comprehensive patent search
 
Regulatory and Quality Affairs: Answers to FDA and ISO Gray Areas
Regulatory and Quality Affairs: Answers to FDA and ISO Gray AreasRegulatory and Quality Affairs: Answers to FDA and ISO Gray Areas
Regulatory and Quality Affairs: Answers to FDA and ISO Gray Areas
 
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...
Additive Manufacturing Discussion Panel – Developing a Roadmap for Regulatory...
 
Rifaximin - Comprehensive patent search
Rifaximin  - Comprehensive patent searchRifaximin  - Comprehensive patent search
Rifaximin - Comprehensive patent search
 
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017Avoid Post-M&A Supply Chain Surprises - OMTEC 2017
Avoid Post-M&A Supply Chain Surprises - OMTEC 2017
 
The CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsThe CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory Affairs
 
Dr. Piotr Iwanowski - 6th Clinical Research Conference
Dr. Piotr Iwanowski - 6th Clinical Research ConferenceDr. Piotr Iwanowski - 6th Clinical Research Conference
Dr. Piotr Iwanowski - 6th Clinical Research Conference
 
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final
2015-CLSA-Report-Recent-Trends-in-FDA-Med-Device-Regulation-Final
 
RAC US Study Guide
RAC US Study GuideRAC US Study Guide
RAC US Study Guide
 
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
 
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
 
Chelsea Therapeutics - Northera NOH 2011 Market Research Plan
Chelsea Therapeutics -  Northera NOH 2011 Market Research PlanChelsea Therapeutics -  Northera NOH 2011 Market Research Plan
Chelsea Therapeutics - Northera NOH 2011 Market Research Plan
 
What is pca pdf
What is pca pdfWhat is pca pdf
What is pca pdf
 

Viewers also liked

PROFESSOR HELANDERSON SOUSAx
PROFESSOR HELANDERSON SOUSAxPROFESSOR HELANDERSON SOUSAx
PROFESSOR HELANDERSON SOUSAxDayanne Sousa
 
Wordpress blog
Wordpress blogWordpress blog
Wordpress blogamdavi
 
August 2010 Newsletter
August 2010 NewsletterAugust 2010 Newsletter
August 2010 Newsletterkhorton123
 
Tni Uk Pensions Flyer 0111
Tni   Uk Pensions Flyer 0111Tni   Uk Pensions Flyer 0111
Tni Uk Pensions Flyer 0111GJGrey
 
Informatica oli pro
Informatica oli proInformatica oli pro
Informatica oli prosanz07
 
Volkshilfe Sozialbarometer zum Thema Verteilung & Vermögenssteuer
Volkshilfe Sozialbarometer zum Thema Verteilung & VermögenssteuerVolkshilfe Sozialbarometer zum Thema Verteilung & Vermögenssteuer
Volkshilfe Sozialbarometer zum Thema Verteilung & VermögenssteuerVolkshilfe Österreich
 
Programa tarteso
Programa tartesoPrograma tarteso
Programa tartesofjgn1972
 
Componentes de un equipo de computo
Componentes de un equipo de computoComponentes de un equipo de computo
Componentes de un equipo de computoCOBACH 28
 
Gráfico diario del ibex 35 para el 02 11 2011
Gráfico diario del ibex 35 para el  02 11 2011Gráfico diario del ibex 35 para el  02 11 2011
Gráfico diario del ibex 35 para el 02 11 2011Experiencia Trading
 
7bd spelling lesson 10
7bd spelling lesson 107bd spelling lesson 10
7bd spelling lesson 10vickytg123
 
gestion basica de informacion
gestion basica de informaciongestion basica de informacion
gestion basica de informacionkmilokruzz
 
Local de prova enade 2011
Local de prova enade 2011Local de prova enade 2011
Local de prova enade 2011CA Tce Ifpb
 

Viewers also liked (20)

PROFESSOR HELANDERSON SOUSAx
PROFESSOR HELANDERSON SOUSAxPROFESSOR HELANDERSON SOUSAx
PROFESSOR HELANDERSON SOUSAx
 
Wordpress blog
Wordpress blogWordpress blog
Wordpress blog
 
August 2010 Newsletter
August 2010 NewsletterAugust 2010 Newsletter
August 2010 Newsletter
 
Tni Uk Pensions Flyer 0111
Tni   Uk Pensions Flyer 0111Tni   Uk Pensions Flyer 0111
Tni Uk Pensions Flyer 0111
 
Informatica oli pro
Informatica oli proInformatica oli pro
Informatica oli pro
 
Volkshilfe Sozialbarometer zum Thema Verteilung & Vermögenssteuer
Volkshilfe Sozialbarometer zum Thema Verteilung & VermögenssteuerVolkshilfe Sozialbarometer zum Thema Verteilung & Vermögenssteuer
Volkshilfe Sozialbarometer zum Thema Verteilung & Vermögenssteuer
 
Programa tarteso
Programa tartesoPrograma tarteso
Programa tarteso
 
Mein trip nach Afrika
Mein trip nach AfrikaMein trip nach Afrika
Mein trip nach Afrika
 
Componentes de un equipo de computo
Componentes de un equipo de computoComponentes de un equipo de computo
Componentes de un equipo de computo
 
Reencuentro 2011
Reencuentro 2011Reencuentro 2011
Reencuentro 2011
 
Daniela Tenecora
Daniela Tenecora Daniela Tenecora
Daniela Tenecora
 
Gráfico diario del ibex 35 para el 02 11 2011
Gráfico diario del ibex 35 para el  02 11 2011Gráfico diario del ibex 35 para el  02 11 2011
Gráfico diario del ibex 35 para el 02 11 2011
 
7bd spelling lesson 10
7bd spelling lesson 107bd spelling lesson 10
7bd spelling lesson 10
 
Hub concept 01.08.12
Hub concept 01.08.12Hub concept 01.08.12
Hub concept 01.08.12
 
BUSQUEDA EN INTERNET
BUSQUEDA EN INTERNETBUSQUEDA EN INTERNET
BUSQUEDA EN INTERNET
 
gestion basica de informacion
gestion basica de informaciongestion basica de informacion
gestion basica de informacion
 
Inde xscan ngconsolida20111101
Inde xscan ngconsolida20111101Inde xscan ngconsolida20111101
Inde xscan ngconsolida20111101
 
Local de prova enade 2011
Local de prova enade 2011Local de prova enade 2011
Local de prova enade 2011
 
Abolitionist reward
Abolitionist rewardAbolitionist reward
Abolitionist reward
 
File 13
File 13File 13
File 13
 

Similar to January 2010 Newsletter

Subject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney SparksSubject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney SparksRodney Sparks
 
Infringement of patents and remedies
Infringement of patents and remediesInfringement of patents and remedies
Infringement of patents and remediesatuljaybhaye
 
Premarket Notification The 510(k) Process
Premarket Notification The 510(k) ProcessPremarket Notification The 510(k) Process
Premarket Notification The 510(k) ProcessMichael Swit
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (BhanuSriChandanaKnch
 
IP business transaction slides
IP business transaction slidesIP business transaction slides
IP business transaction slidesMarta Delsignore
 
May 2010 Newsletter
May 2010 NewsletterMay 2010 Newsletter
May 2010 Newsletterkhorton123
 
Anda 120822221703-phpapp01
Anda 120822221703-phpapp01Anda 120822221703-phpapp01
Anda 120822221703-phpapp01Deshmukh Ishrar
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceMoremrunal
 
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...Knobbe Martens - Intellectual Property Law
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Sagar Savale
 
Patents & drug act 1970. Ph. Jurisprudence
Patents & drug act 1970. Ph. JurisprudencePatents & drug act 1970. Ph. Jurisprudence
Patents & drug act 1970. Ph. JurisprudenceSriRamyaVaddiparthy
 
The wrong way and right way of retaining a testing laboratory
The wrong way and right way of retaining a testing laboratoryThe wrong way and right way of retaining a testing laboratory
The wrong way and right way of retaining a testing laboratoryKristal Snider
 
UK FCA Sandbox Overview
UK FCA Sandbox OverviewUK FCA Sandbox Overview
UK FCA Sandbox OverviewOxbow Partners
 

Similar to January 2010 Newsletter (20)

Subject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney SparksSubject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney Sparks
 
Infringement of patents and remedies
Infringement of patents and remediesInfringement of patents and remedies
Infringement of patents and remedies
 
Premarket Notification The 510(k) Process
Premarket Notification The 510(k) ProcessPremarket Notification The 510(k) Process
Premarket Notification The 510(k) Process
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (
 
IP business transaction slides
IP business transaction slidesIP business transaction slides
IP business transaction slides
 
May 2010 Newsletter
May 2010 NewsletterMay 2010 Newsletter
May 2010 Newsletter
 
Anda 120822221703-phpapp01
Anda 120822221703-phpapp01Anda 120822221703-phpapp01
Anda 120822221703-phpapp01
 
IPR NDA and ANDA
IPR NDA and ANDAIPR NDA and ANDA
IPR NDA and ANDA
 
Remedies and commitments in abuse cases – PISARKIEWICZ – December 2022 OECD d...
Remedies and commitments in abuse cases – PISARKIEWICZ – December 2022 OECD d...Remedies and commitments in abuse cases – PISARKIEWICZ – December 2022 OECD d...
Remedies and commitments in abuse cases – PISARKIEWICZ – December 2022 OECD d...
 
ANDA
ANDAANDA
ANDA
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillance
 
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...
Preparing for Biosimilars: Key Points for Participating in the U.S. Regulator...
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Naresh... anda ppt
 
Anda ppt
Anda pptAnda ppt
Anda ppt
 
Patents & drug act 1970. Ph. Jurisprudence
Patents & drug act 1970. Ph. JurisprudencePatents & drug act 1970. Ph. Jurisprudence
Patents & drug act 1970. Ph. Jurisprudence
 
The wrong way and right way of retaining a testing laboratory
The wrong way and right way of retaining a testing laboratoryThe wrong way and right way of retaining a testing laboratory
The wrong way and right way of retaining a testing laboratory
 
UK FCA Sandbox Overview
UK FCA Sandbox OverviewUK FCA Sandbox Overview
UK FCA Sandbox Overview
 
Regulatory 101
Regulatory 101 Regulatory 101
Regulatory 101
 
SchY.ppt
SchY.pptSchY.ppt
SchY.ppt
 

More from khorton123

Q3 2014 IP Legal Minute
Q3 2014 IP Legal MinuteQ3 2014 IP Legal Minute
Q3 2014 IP Legal Minutekhorton123
 
Q2 2014 IP Legal Minute
Q2 2014 IP Legal MinuteQ2 2014 IP Legal Minute
Q2 2014 IP Legal Minutekhorton123
 
Q4 2012 IP Strategy Newsletter
Q4 2012 IP Strategy NewsletterQ4 2012 IP Strategy Newsletter
Q4 2012 IP Strategy Newsletterkhorton123
 
October 2012 IP Legal Minute
October 2012 IP Legal MinuteOctober 2012 IP Legal Minute
October 2012 IP Legal Minutekhorton123
 
August 2012 IP Legal Minute
August 2012 IP Legal MinuteAugust 2012 IP Legal Minute
August 2012 IP Legal Minutekhorton123
 
July 2012 IP Legal Minute
July 2012 IP Legal MinuteJuly 2012 IP Legal Minute
July 2012 IP Legal Minutekhorton123
 
June 2012 IP Legal Minute
June 2012 IP Legal MinuteJune 2012 IP Legal Minute
June 2012 IP Legal Minutekhorton123
 
Q3 2012 IP Strategy Newsletter
Q3 2012 IP Strategy NewsletterQ3 2012 IP Strategy Newsletter
Q3 2012 IP Strategy Newsletterkhorton123
 
May 2012 IP Legal Minute
May 2012 IP Legal MinuteMay 2012 IP Legal Minute
May 2012 IP Legal Minutekhorton123
 
April 2012 IP Legal Minute
April 2012 IP Legal MinuteApril 2012 IP Legal Minute
April 2012 IP Legal Minutekhorton123
 
March 2012 IP Legal Minute
March 2012 IP Legal MinuteMarch 2012 IP Legal Minute
March 2012 IP Legal Minutekhorton123
 
Q2 2012 IP Strategy Newsletter
Q2 2012 IP Strategy NewsletterQ2 2012 IP Strategy Newsletter
Q2 2012 IP Strategy Newsletterkhorton123
 
Q1 2012 IP Strategy Minute
Q1 2012 IP Strategy MinuteQ1 2012 IP Strategy Minute
Q1 2012 IP Strategy Minutekhorton123
 
February 2012 IP Legal Minute
February 2012 IP Legal MinuteFebruary 2012 IP Legal Minute
February 2012 IP Legal Minutekhorton123
 
January 2012 IP Minute Newsletter
January 2012  IP Minute NewsletterJanuary 2012  IP Minute Newsletter
January 2012 IP Minute Newsletterkhorton123
 
December 2011 Newsletter
December 2011 NewsletterDecember 2011 Newsletter
December 2011 Newsletterkhorton123
 
November 2011 Newsletter
November 2011 NewsletterNovember 2011 Newsletter
November 2011 Newsletterkhorton123
 
December 2010 Newsletter
December 2010 NewsletterDecember 2010 Newsletter
December 2010 Newsletterkhorton123
 
March 2010 Newsletter
March 2010 NewsletterMarch 2010 Newsletter
March 2010 Newsletterkhorton123
 
April 2010 Newsletter
April 2010 NewsletterApril 2010 Newsletter
April 2010 Newsletterkhorton123
 

More from khorton123 (20)

Q3 2014 IP Legal Minute
Q3 2014 IP Legal MinuteQ3 2014 IP Legal Minute
Q3 2014 IP Legal Minute
 
Q2 2014 IP Legal Minute
Q2 2014 IP Legal MinuteQ2 2014 IP Legal Minute
Q2 2014 IP Legal Minute
 
Q4 2012 IP Strategy Newsletter
Q4 2012 IP Strategy NewsletterQ4 2012 IP Strategy Newsletter
Q4 2012 IP Strategy Newsletter
 
October 2012 IP Legal Minute
October 2012 IP Legal MinuteOctober 2012 IP Legal Minute
October 2012 IP Legal Minute
 
August 2012 IP Legal Minute
August 2012 IP Legal MinuteAugust 2012 IP Legal Minute
August 2012 IP Legal Minute
 
July 2012 IP Legal Minute
July 2012 IP Legal MinuteJuly 2012 IP Legal Minute
July 2012 IP Legal Minute
 
June 2012 IP Legal Minute
June 2012 IP Legal MinuteJune 2012 IP Legal Minute
June 2012 IP Legal Minute
 
Q3 2012 IP Strategy Newsletter
Q3 2012 IP Strategy NewsletterQ3 2012 IP Strategy Newsletter
Q3 2012 IP Strategy Newsletter
 
May 2012 IP Legal Minute
May 2012 IP Legal MinuteMay 2012 IP Legal Minute
May 2012 IP Legal Minute
 
April 2012 IP Legal Minute
April 2012 IP Legal MinuteApril 2012 IP Legal Minute
April 2012 IP Legal Minute
 
March 2012 IP Legal Minute
March 2012 IP Legal MinuteMarch 2012 IP Legal Minute
March 2012 IP Legal Minute
 
Q2 2012 IP Strategy Newsletter
Q2 2012 IP Strategy NewsletterQ2 2012 IP Strategy Newsletter
Q2 2012 IP Strategy Newsletter
 
Q1 2012 IP Strategy Minute
Q1 2012 IP Strategy MinuteQ1 2012 IP Strategy Minute
Q1 2012 IP Strategy Minute
 
February 2012 IP Legal Minute
February 2012 IP Legal MinuteFebruary 2012 IP Legal Minute
February 2012 IP Legal Minute
 
January 2012 IP Minute Newsletter
January 2012  IP Minute NewsletterJanuary 2012  IP Minute Newsletter
January 2012 IP Minute Newsletter
 
December 2011 Newsletter
December 2011 NewsletterDecember 2011 Newsletter
December 2011 Newsletter
 
November 2011 Newsletter
November 2011 NewsletterNovember 2011 Newsletter
November 2011 Newsletter
 
December 2010 Newsletter
December 2010 NewsletterDecember 2010 Newsletter
December 2010 Newsletter
 
March 2010 Newsletter
March 2010 NewsletterMarch 2010 Newsletter
March 2010 Newsletter
 
April 2010 Newsletter
April 2010 NewsletterApril 2010 Newsletter
April 2010 Newsletter
 

January 2010 Newsletter

  • 1. THE INTELLECTUAL PROPERTY MINUTE JANUARY 2010: RESTRICTION PRACTICE We have seen the increasing use of restriction and election of species requirement by patent examiners over the last several years. Here are some suggestions for preventing and overcoming restriction requirements. Pre-Restriction When drafting the patent application, prepare method and product claims so they contain as many similar limitations as possible. This technique will reduce the ability for the examiner to say that the method as claimed can be used to make a different product or that the product as claimed can be made by a different method. Also, to anticipate an election of species requirement, draft one claim as broad as possible so that it can be considered a generic claim and also include a linking claim. Replying to Restrictions On receipt of a restriction requirement, take a hard look at the requirement itself and the underlying reasoning. Some of the mistakes made by Examiners include: (1) applying PCT rules to U.S. applications, (2) not accounting for all generic or linking claims, (3) forcing a species election where they are not mutually exclusive, (4) imposing a restriction rather than an election of species, and (5) not providing sufficient reasoning to support the argument that the method as claimed can be used to make a different product or that the product as claimed can be made by a different method. Look for generic claims and linking claims that can be used to limit the impact of the restriction requirement. And remember, there is nothing precluding you from amending the claims to defeat the restriction requirement, i.e., adding a generic claim or a linking claim, as well as amending the generic claim to include all of the species. 90% of the time, one of these problems exist and can be used as a basis for traversing the restricting requirement. Post-Restriction Win or lose, there are certain actions that can be taken lessen the impact of restriction practice. For an election of specie requirement, make sure that the generic claim is an independent claim that contains both the elected specie and the non-elected specie(s). When the elected specie has been allowed, the Examiner must examine the non-elected species. But if the claim is already an independent claim, and the Examiner has already determined it is allowable, the Examiner will likely do nothing more. But if the elected specie is in a dependent claim, the Examiner will continue the examination process. Also keep in mind your ability to take advantage of rejoinder practice. With rejoinders, the Applicant can rejoin claims after the product and method claims have been restricted. Where the Applicant elected and obtained allowance of a product claim, the process claims may be rejoined provided that the process claims depend from or include all the limitations of the allowable product claim. The best method for keeping rejoinder a viable option is to not cancel the method claims; rather, continue to amend the method claims throughout prosecution.